PMID- 34504425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210911
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction 
      Induced by anti-PD-1 Immunotherapy in a Cervical Cancer Patient.
PG  - 707967
LID - 10.3389/fphar.2021.707967 [doi]
LID - 707967
AB  - Background: Anti-programmed cell death protein 1 (PD-1) has been successfully 
      used in carcinomas treatment. However, it causes significant adverse effects 
      (AEs), including cutaneous reactions, particularly the life-threatening severe 
      bullous skin reactions (SBSR) and toxic epidermal necrolysis (TEN). Case summary: 
      Herein, we described for the first time a case report of SBSR induced by 
      anti-PD-1 therapy in a cervical cancer patient. In addition, we revised existing 
      literature on anti-PD-1 induced cutaneous reactions. We reported a cervical 
      cancer patient who was treated with four successive cycles of Sintilimab and 
      Toripalimab injections and developed systemic rashes, bullae, and epidermal 
      desquamation, which worsened and led to infection, eventually causing death after 
      being unresponsive to aggressive treatments. Conclusion: Anti-PD-1 antibodies 
      commonly cause skin toxicity effects, some of which may be deadly. Therefore, 
      healthcare providers should observe early symptoms and administer proper 
      treatment to prevent aggravation of symptoms.
CI  - Copyright (c) 2021 Li, Qu, Ren and Hu.
FAU - Li, Xiang
AU  - Li X
AD  - The Fifth Department of Oncology, Jinshazhou Hospital of Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Qu, Li-Xin
AU  - Qu LX
AD  - The Fifth Department of Oncology, Jinshazhou Hospital of Guangzhou University of 
      Chinese Medicine, Guangzhou, China.
FAU - Ren, Yu-Mei
AU  - Ren YM
AD  - The Second Clinical Medical College, Henan University of Chinese Medicine, 
      Zhengzhou, China.
AD  - Pediatric Ward, Henan Province Hospital of TCM, Zhengzhou, China.
FAU - Hu, Chang
AU  - Hu C
AD  - Department of Oncology, Fuda Cancer Hospital Guangzhou, Guangzhou, China.
LA  - eng
PT  - Case Reports
DEP - 20210824
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8423354
OTO - NOTNLM
OT  - PD-1
OT  - case report
OT  - cervical cancer
OT  - literature review
OT  - severe bullous skin reactions
OT  - toxic epidermal necrolysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/11 06:00
MHDA- 2021/09/11 06:01
PMCR- 2021/08/24
CRDT- 2021/09/10 06:59
PHST- 2021/05/11 00:00 [received]
PHST- 2021/08/12 00:00 [accepted]
PHST- 2021/09/10 06:59 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/09/11 06:01 [medline]
PHST- 2021/08/24 00:00 [pmc-release]
AID - 707967 [pii]
AID - 10.3389/fphar.2021.707967 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Aug 24;12:707967. doi: 10.3389/fphar.2021.707967. 
      eCollection 2021.